Abbott Atrasentan Meta-Analysis Of Failed Trials Is "Centerpiece" Of NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott will complete the NDA filing for Xinlay (atrasentan) in metastatic hormone-refractory prostate cancer by year-end, ahead of the 2005 timetable predicted after its pivotal trial in the indication failed to reach statistical significance.